The hepatology history follows the same H&P skeleton you already know — but each section has liver-specific inflection points that most standard curricula miss. Mastering them changes how quickly you identify and risk-stratify liver disease in any clinical setting.
Elicit a liver-focused history covering alcohol use, medication and supplement hepatotoxicity, and metabolic risk factors
Apply validated alcohol screening tools (AUDIT-C) to quantify intake and stratify liver disease risk
Formulate a prioritized differential diagnosis for elevated liver enzymes based on history findings alone
18 min · 9 sectionsClinical Skills
Reading mode
On this page
00Clinical Case
01Why the Hepatology History Is Different
02Chief Complaint & HPI
03Past Medical History
04Past Surgical History
05Medications & Supplements
06Social History
07Family History
08Review of Systems
Progress0/9
Clinical Case — Frame the Topic
You are a third-year medical student on your internal medicine rotation. Your attending hands you a chart: a 45-year-old man with a BMI of 32, type 2 diabetes, and an incidental finding of ALT 84 U/L on a routine pre-operative metabolic panel. He takes atorvastatin, metformin, and "some supplements from the gym." He drinks "socially."
As you read through the sections below, think about what specific questions you would ask in each part of the H&P. What does "social drinking" mean, and how do you quantify it? Which supplement would concern you most? What historical clue would change your workup from MASLD to something more urgent?
Choose a clinical scenario — sections below will load tailored questions
Liver disease is frequently silent until decompensation. By the time jaundice, ascites, or encephalopathy appear, significant fibrosis has often already occurred. A thorough, targeted history is your most powerful early detection tool — and it requires probing areas that the standard systems review underemphasizes.
The sections below follow standard H&P order. Use the compact scenario toggle at the top of each section to load key questions tailored to the clinical scenario you're working up.
Scenario:
Most patients with liver disease do not present with a liver complaint. They present with fatigue, an abnormal lab, or an incidental imaging finding. Establish what brought them in, then trace the timeline of symptoms and prior testing. Key symptoms to ask about regardless of scenario: jaundice or scleral icterus, abdominal distension, fatigue, pruritus, dark urine, pale or clay-colored stools, right upper quadrant discomfort, confusion or personality change, and any history of hematemesis or melena.
Key Questions — Elevated Liver Enzymes
Were you told about this finding by your doctor? Do you have any symptoms, or was this picked up incidentally?
Have you noticed any fatigue, nausea, or right-sided abdominal discomfort?
Any yellowing of your eyes or skin, even transiently?
Any dark urine or pale/clay-colored stools? (suggests cholestasis)
How long ago were these labs drawn? Have they been repeated or were they previously normal?
Has anyone ever told you before that your liver tests were abnormal?
Scenario:
Identify conditions that are either a cause of liver disease or that complicate its management. The metabolic syndrome cluster — type 2 diabetes, obesity, hypertension, and hypertriglyceridemia — is the most common background for metabolic dysfunction-associated steatotic liver disease (MASLD), now the most prevalent liver disease in the US. Also ask about prior liver-related diagnoses, hospitalizations, and whether the patient has had imaging of their abdomen before.
Key Questions — Elevated Liver Enzymes
Do you have type 2 diabetes, high blood pressure, or high cholesterol/triglycerides?
Any prior history of abnormal liver tests? Were they ever investigated?
Any history of thyroid disease (hypothyroidism is associated with MASLD), celiac disease, or inflammatory bowel disease (IBD)? (IBD is associated with primary sclerosing cholangitis, or PSC)
Any prior abdominal imaging — ultrasound, CT, MRI — that showed changes in the liver?
Any history of heart failure (congestive hepatopathy) or blood clots (Budd-Chiari)?
Scenario:
Abdominal surgical history is directly relevant in hepatology. Prior procedures can be a clue to etiology, alter management options, and are critical information for transplant evaluation. Always ask about biliary procedures specifically, as cholecystectomy and biliary reconstructions are often not volunteered.
Key Questions — Elevated Liver Enzymes
Have you had your gallbladder removed (cholecystectomy)? Any other biliary procedures?
Any bariatric surgery (gastric bypass, sleeve gastrectomy)? The rapid post-operative weight loss phase can paradoxically worsen hepatic inflammation before improving it. Roux-en-Y gastric bypass also significantly alters oral drug bioavailability. Additionally, patients who have undergone bariatric surgery are at substantially increased risk of developing alcohol use disorder, due to altered alcohol absorption and first-pass metabolism.
Any prior abdominal surgery that might have involved the liver or bile ducts?
Any blood transfusions during surgery, particularly before 1992? (HCV risk)
Scenario:
Drug-induced liver injury (DILI) is underrecognized because patients do not volunteer supplement use, and providers do not always ask. You must ask explicitly and by category. Acetaminophen is the most common cause of acute liver failure in the United States — always quantify total daily dose across all products (cold medicines, PM formulations, prescription combination drugs). Herbal and dietary supplements (green tea extract, kava, pyrrolizidine alkaloids, anabolic supplements) are an increasingly important cause of DILI and require specific questioning. Consult LiverTox for any agent you're unsure about.
Key Questions — Elevated Liver Enzymes
"Tell me every supplement you take, even if you consider it natural or herbal."
"How much acetaminophen or Tylenol do you take in a day? Do you take any cold medicines, PM sleep aids, or prescription pain medications that might contain it?"
"Have you started any new medications in the last 6 months?" (DILI can have a delayed presentation of weeks to months)
Ask specifically about: statins, nitrofurantoin, isoniazid, amiodarone, methotrexate (common hepatotoxins), and any anabolic or bodybuilding supplements.
Ask about nonsteroidal anti-inflammatory drugs (NSAIDs) — they can cause direct hepatotoxicity and significantly impair renal function in patients with underlying liver disease.
Scenario:
Social history in hepatology is unusually high-yield. Alcohol use, substance use, and infectious exposures — all covered here — are the dominant etiologic drivers of liver disease. Ask without judgment and explain why you're asking. Patients are more forthcoming when they understand the clinical reason for the question. Also establish baseline social support, since patients with cirrhosis in particular require significant support networks for medication adherence, procedure logistics, and transplant eligibility.
Alcohol
Asking "do you drink?" is insufficient. You need quantity, frequency, duration, and pattern. Two validated screens — a positive result on either triggers fuller assessment (AUDIT-10, addiction referral):
Screening tool
Positive screen
Notes
AUDIT-C
≥3 (women) · ≥4 (men)
Three items — frequency, quantity, binge. The lower female threshold reflects differences in alcohol metabolism.
CAGE
≥2 "yes" answers
Cut down · Annoyed · Guilty · Eye-opener. Single, sex-independent threshold.
Then quantify in standard drinks per week. One US standard drink = 14 g of pure ethanol (definitions vary internationally: ~8 g UK, ~10 g Australia, ~12 g Sweden — verify locally). Heavy use is >7 drinks/week in women and >14 drinks/week in men.
Beverage
Serving = 1 standard drink
Typical ABV
Regular beer
12 oz (355 mL)
~5%
Wine
5 oz (150 mL)
~12%
Distilled spirits
1.5 oz (44 mL)
~40%
Also establish pattern (daily vs. binge drinking carry different risks and prognostic implications) and timeline (duration of heavy use correlates with fibrosis burden).
Substance Use & Infectious Exposures
Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain leading causes of cirrhosis and hepatocellular carcinoma (HCC) globally. Exposures are primarily behavioral and geographic — and require a targeted history:
Birth country: HBV is endemic in sub-Saharan Africa and Southeast and East Asia; vertical transmission is the dominant route.
HCV screening: The CDC recommends at least one lifetime HCV screening test for all adults ≥18 years, regardless of risk factors. Those with ongoing risk behaviors should be screened periodically.
IV drug use, past or present, even a single episode (HCV, HBV)
High-risk sexual behavior, history of sexually transmitted infections (STIs) (HBV)
Blood transfusion prior to 1992 (HCV screening was not yet universal)
Healthcare worker exposures, tattoos, piercings in unregulated settings
Cocaine use (direct hepatotoxin), anabolic steroid use
Key Questions — Elevated Liver Enzymes
"How many drinks do you have in a typical week? Has that changed recently?"
"Have you ever used IV drugs, even once?"
"Where were you born?" (HBV: endemic in sub-Saharan Africa and parts of Asia)
"Are you up to date on your hepatitis A and B vaccines?"
"Do you use any recreational drugs, including cocaine, marijuana, or anabolic steroids?"
"What do you do for work? Any exposure to chemicals, solvents, or toxins?"
Scenario:
Hereditary liver diseases are underdiagnosed, often because they are not asked about. Hemochromatosis (HFE mutations) is the most common genetic liver disease in people of Northern European ancestry and is frequently missed for years. Wilson's disease and alpha-1 antitrypsin deficiency should be considered in younger patients. A family history of autoimmune conditions raises the prior probability of autoimmune hepatitis, primary biliary cholangitis (PBC), or PSC.
Disease
Inheritance
Key clue to ask about
First test
Hereditary hemochromatosis
Autosomal recessive
Iron overload in a relative; Northern European ancestry
Iron studies (transferrin sat >45%, ferritin) → HFE genotype
Wilson's disease
Autosomal recessive
Liver disease before age 40; neuropsychiatric change
Ceruloplasmin + 24-hour urine copper
Alpha-1 antitrypsin deficiency
Autosomal co-dominant
Combined lung + liver disease
Serum A1AT level + Pi phenotype
Autoimmune (AIH / PBC / PSC)
Polygenic / familial
Personal or family autoimmune disease (thyroid, IBD, RA)
Autoantibodies (ANA/ASMA, AMA); MRCP if PSC suspected
Key Questions — Elevated Liver Enzymes
"Has anyone in your family been diagnosed with hemochromatosis (iron overload) or told they store too much iron?"
"Any family history of Wilson's disease, or liver disease in someone young?" (Wilson's typically presents before age 40)
"Any alpha-1 antitrypsin deficiency in the family, or anyone with both lung and liver disease?"
"Any family history of autoimmune conditions — thyroid disease, lupus, IBD, rheumatoid arthritis?" (raises suspicion for autoimmune hepatitis, PBC, PSC)
"Any liver or bile duct cancers in first-degree relatives?"
Scenario:
The ROS in hepatology serves two functions: identifying symptoms that suggest advanced or decompensated disease, and uncovering findings that point toward specific etiologies. A targeted organ-system sweep should cover the gastrointestinal, integumentary, neurological, and constitutional domains at minimum.
Key Questions — Elevated Liver Enzymes
GI: Nausea, anorexia, early satiety, RUQ discomfort, change in stool color?
Cholestatic symptoms: Pruritus (particularly at night), dark urine, pale or clay-colored stools?
Skin: Jaundice, easy bruising, xanthelasma (PBC)?
Musculoskeletal: Joint pain or swelling? (Hemochromatosis — metacarpophalangeal, or MCP, joints; autoimmune hepatitis — migratory polyarthritis)
Endocrine: New or worsening diabetes, irregular periods? (MASLD association)
Case Resolution — Elevated Liver Enzymes
A 45-year-old with a BMI of 34, type 2 diabetes, and an ALT of 68 is a very different clinical problem from a 28-year-old with the same ALT who takes bodybuilding supplements.
Metabolic patient: History points to MASLD — calculate FIB-4 (Fibrosis-4 Index), consider referral if score >1.30
Supplement user: Suspect DILI — cross-reference every agent on LiverTox; stop the offending agent; recheck liver function tests (LFTs) in 4–6 weeks
Patient born in Vietnam in 1970: Check hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) first, before metabolic workup
Patient on nitrofurantoin for 18 months: High suspicion for drug-induced autoimmune hepatitis — the history unlocks the diagnosis
The history doesn't just establish diagnosis — it determines urgency, workup sequence, and whether specialist referral is needed now or can wait.
Self-Assessment — Flip Cards
Tap each card to reveal the answer and explanation.
Quick recall
≥3 for women, ≥4 for men
The AUDIT-C uses three questions about alcohol frequency, quantity, and binge drinking. A score of ≥3 in women or ≥4 in men constitutes a positive screen for hazardous or harmful alcohol use and warrants further clinical assessment. The lower threshold for women reflects documented physiologic differences in alcohol metabolism and greater susceptibility to alcohol-related organ injury at equivalent intake levels. The CAGE questionnaire uses a single threshold: ≥2 "yes" answers is a positive screen regardless of sex. (Bush et al., Archives of Internal Medicine 1998; doi:10.1001/archinte.158.16.1789)
The AUDIT-C (Alcohol Use Disorders Identification Test — Concise) uses different positive screen thresholds based on biological sex. What is the correct pairing of cutoff scores?
Tap to reveal →
≥3 for women, ≥4 for men
The AUDIT-C uses three questions about alcohol frequency, quantity, and binge drinking. A score of ≥3 in women or ≥4 in men constitutes a positive screen for hazardous or harmful alcohol use and warrants further clinical assessment. The lower threshold for women reflects documented physiologic differences in alcohol metabolism and greater susceptibility to alcohol-related organ injury at equivalent intake levels. The CAGE questionnaire uses a single threshold: ≥2 "yes" answers is a positive screen regardless of sex. (Bush et al., Archives of Internal Medicine 1998; doi:10.1001/archinte.158.16.1789)
They should be asked about explicitly by category — they are a recognized and increasingly common cause of DILI
Herbal and dietary supplements are a growing cause of DILI and are frequently underreported because patients do not consider them "medications." The DILIN prospective study found that herbal and dietary supplements accounted for approximately 20% of DILI cases. DILI latency can range from days to months, so the medication history must cover at least the past 6 months. Acetaminophen is the leading cause of acute liver failure in the US; the total daily dose must always be quantified across all products that may contain it. (Chalasani et al., Gastroenterology 2015; doi:10.1053/j.gastro.2015.03.006)
A 31-year-old man with elevated ALT reports taking several "gym supplements" daily. When taking a medication history in a patient with suspected drug-induced liver injury (DILI), what is the correct approach to herbal and dietary supplements?
Tap to reveal →
They should be asked about explicitly by category — they are a recognized and increasingly common cause of DILI
Herbal and dietary supplements are a growing cause of DILI and are frequently underreported because patients do not consider them "medications." The DILIN prospective study found that herbal and dietary supplements accounted for approximately 20% of DILI cases. DILI latency can range from days to months, so the medication history must cover at least the past 6 months. Acetaminophen is the leading cause of acute liver failure in the US; the total daily dose must always be quantified across all products that may contain it. (Chalasani et al., Gastroenterology 2015; doi:10.1053/j.gastro.2015.03.006)
Hepatitis B surface antigen (HBsAg) and anti-HBc total
Chronic hepatitis B (HBV) is frequently acquired through perinatal vertical transmission from an infected mother and can remain asymptomatic for decades. Key history elements that raise suspicion include: unvaccinated status, a family member with chronic liver disease or "hepatitis," and birth or early childhood in a region with high HBV endemicity (Southeast and East Asia, sub-Saharan Africa, Pacific Islands). This patient's combination of no childhood HBV vaccination and a mother with a chronic liver condition together make HBV the leading etiology to rule out. HBsAg detects active infection; anti-HBc total detects both current and past infection. Chronic HBV is frequently asymptomatic until cirrhosis or HCC develops — testing must not wait for symptoms. Wilson's disease is worth considering in young patients with unexplained liver disease but is not the priority given the exposure history here. (Terrault et al., Hepatology 2018; doi:10.1002/hep.29800)
A 28-year-old woman presents with an ALT of 95 U/L and no metabolic risk factors. She drinks minimally. When taking her history, she mentions she was not vaccinated against hepatitis B as a child and that her mother was treated for a chronic liver condition. Which test should be ordered first?
Tap to reveal →
Hepatitis B surface antigen (HBsAg) and anti-HBc total
Chronic hepatitis B (HBV) is frequently acquired through perinatal vertical transmission from an infected mother and can remain asymptomatic for decades. Key history elements that raise suspicion include: unvaccinated status, a family member with chronic liver disease or "hepatitis," and birth or early childhood in a region with high HBV endemicity (Southeast and East Asia, sub-Saharan Africa, Pacific Islands). This patient's combination of no childhood HBV vaccination and a mother with a chronic liver condition together make HBV the leading etiology to rule out. HBsAg detects active infection; anti-HBc total detects both current and past infection. Chronic HBV is frequently asymptomatic until cirrhosis or HCC develops — testing must not wait for symptoms. Wilson's disease is worth considering in young patients with unexplained liver disease but is not the priority given the exposure history here. (Terrault et al., Hepatology 2018; doi:10.1002/hep.29800)
This metabolic syndrome cluster — type 2 diabetes, obesity, hypertension, and hypertriglyceridemia — is the most common background for MASLD, now the most prevalent liver disease in the US
MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) is now the most prevalent chronic liver disease in the United States, affecting approximately 25–30% of the adult population. Its development is driven by systemic metabolic dysfunction — the same pathophysiologic milieu as the metabolic syndrome. The PMH section of the hepatology H&P explicitly identifies the four-component metabolic cluster (T2DM, obesity, hypertension, and hypertriglyceridemia) as the most important background for MASLD. When all four are present in a patient with elevated liver enzymes and no competing etiology, MASLD should be at the top of the differential. The clinical case on this page mirrors this exactly: a 45-year-old man with a BMI of 32, T2DM, and incidental ALT elevation. Additional PMH associations worth asking about include hypothyroidism (independently associated with hepatic steatosis) and celiac disease. The metabolic PMH is not just background information — it is the primary etiology-generating step in the initial liver enzyme workup.
A 45-year-old man with incidentally elevated ALT is referred to your clinic. His past medical history includes type 2 diabetes, hypertension, and a BMI of 32. His lipid panel shows hypertriglyceridemia. He drinks minimally and takes no hepatotoxic supplements. Why does this cluster of findings shape the differential?
Tap to reveal →
This metabolic syndrome cluster — type 2 diabetes, obesity, hypertension, and hypertriglyceridemia — is the most common background for MASLD, now the most prevalent liver disease in the US
MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) is now the most prevalent chronic liver disease in the United States, affecting approximately 25–30% of the adult population. Its development is driven by systemic metabolic dysfunction — the same pathophysiologic milieu as the metabolic syndrome. The PMH section of the hepatology H&P explicitly identifies the four-component metabolic cluster (T2DM, obesity, hypertension, and hypertriglyceridemia) as the most important background for MASLD. When all four are present in a patient with elevated liver enzymes and no competing etiology, MASLD should be at the top of the differential. The clinical case on this page mirrors this exactly: a 45-year-old man with a BMI of 32, T2DM, and incidental ALT elevation. Additional PMH associations worth asking about include hypothyroidism (independently associated with hepatic steatosis) and celiac disease. The metabolic PMH is not just background information — it is the primary etiology-generating step in the initial liver enzyme workup.
Hereditary hemochromatosis — autosomal recessive
Hereditary hemochromatosis (most commonly HFE C282Y homozygosity) is the most common inherited metabolic liver disease, characterized by progressive iron accumulation in the liver, pancreas, heart, joints, and pituitary gland. The combination of markedly elevated transferrin saturation (>45%) and elevated ferritin — particularly with a first-degree relative with iron overload — is the classic presentation. It follows autosomal recessive inheritance, meaning siblings have a 25% chance of being C282Y homozygotes; family testing is therefore essential. Early disease is asymptomatic and detected only through iron studies; if untreated, it leads to cirrhosis, HCC, diabetes, cardiomyopathy, and hypogonadism — all preventable with therapeutic phlebotomy. Wilson's disease (copper overload) would be associated with low ceruloplasmin and elevated 24-hour urine copper. Alpha-1 antitrypsin deficiency causes hepatic and pulmonary disease and is identified by serum A1AT level and phenotyping.
A 45-year-old patient presents with fatigue, elevated ferritin (1,350 ng/mL), and a transferrin saturation of 74%. They mention a sibling was previously told they have "too much iron in the liver." Which hereditary liver disease does this presentation most suggest, and what is its inheritance pattern?
Tap to reveal →
Hereditary hemochromatosis — autosomal recessive
Hereditary hemochromatosis (most commonly HFE C282Y homozygosity) is the most common inherited metabolic liver disease, characterized by progressive iron accumulation in the liver, pancreas, heart, joints, and pituitary gland. The combination of markedly elevated transferrin saturation (>45%) and elevated ferritin — particularly with a first-degree relative with iron overload — is the classic presentation. It follows autosomal recessive inheritance, meaning siblings have a 25% chance of being C282Y homozygotes; family testing is therefore essential. Early disease is asymptomatic and detected only through iron studies; if untreated, it leads to cirrhosis, HCC, diabetes, cardiomyopathy, and hypogonadism — all preventable with therapeutic phlebotomy. Wilson's disease (copper overload) would be associated with low ceruloplasmin and elevated 24-hour urine copper. Alpha-1 antitrypsin deficiency causes hepatic and pulmonary disease and is identified by serum A1AT level and phenotyping.
References
Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789-1795. PubMed 9738608
Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340-1352. PubMed 25754159
National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. www.ncbi.nlm.nih.gov/books/NBK547852/
Ghany MG, Pan CQ, Lok AS, et al. AASLD-IDSA practice guideline on treatment of chronic hepatitis B. Hepatology. 2025;83(4):974-997. PubMed 41186418(current AASLD-IDSA guideline)
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. PubMed 29405329(superseded by the 2025 guideline)